Literature DB >> 12467766

Hepatitis C in the setting of HIV co-infection.

Mandana Khalili1, Brian W Behm.   

Abstract

Hepatitis C virus (HCV) co-infection is common among HIV-infected individuals and can lead to increased morbidity and mortality in this population. HIV adversely impacts the natural history of HCV disease with higher rates of liver disease progression but the effect of HCV on the natural history of HIV is disputed. Additionally, presence of HCV may decrease tolerability of highly active antiretroviral regimens for HIV treatment due to a potential increase in hepatotoxicity. Currently there is limited information available regarding HCV therapy in the setting of HIV co-infection but the HCV virologic response to interferon regimens appears to be similar to those individuals with HCV infection alone. However, additional information is required to assess the efficacy and safety of HCV therapy including possible interaction of HCV and HIV anti-viral medications in these co-infected individuals.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12467766     DOI: 10.1016/s1286-4579(02)01652-0

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  3 in total

1.  The unique HCV genotype distribution and the discovery of a novel subtype 6u among IDUs co-infected with HIV-1 in Yunnan, China.

Authors:  Xueshan Xia; Ling Lu; Kok Keng Tee; Wenhua Zhao; Jianguo Wu; Jing Yu; Xiaojie Li; Yixiong Lin; Muhammad Mahmood Mukhtar; Curt H Hagedorn; Yutaka Takebe
Journal:  J Med Virol       Date:  2008-07       Impact factor: 2.327

2.  Factors associated with liver biopsy performance in HCV-HIV coinfected injecting drug users with HCV viremia: results from a five-year longitudinal assessment.

Authors:  Dominique Rey; Maria-Patrizia Carrieri; Bruno Spire; Sandrine Loubière; Pierre Dellamonica; Hervé Gallais; Gilles-Patrice Cassuto; Jean-Albert Gastaut; Yolande Obadia
Journal:  J Urban Health       Date:  2004-03       Impact factor: 3.671

3.  Pegylated interferon alpha-2a with or without ribavirin in HCV/HIV coinfection: partially blinded, randomized multicenter trial.

Authors:  Mandana Khalili; David Bernstein; Ellen Lentz; Christine Barylski; Margaret Hoffman-Terry
Journal:  Dig Dis Sci       Date:  2005-06       Impact factor: 3.487

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.